MedTrace Logo

Frankincense Supplements and Inflammation

NCT06488417 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-08-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether frankincense essential oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are:

1. Do frankincense essential oil supplements affect gene expression and protein markers as measured in blood?
2. How does daily ingestion of frankincense supplements affect anthropometric measurements, including body mass index, waist circumference, blood pressure, and heart rate?
3. How does daily ingestion of frankincense essential oil supplements affect subjective quality of life and health parameters?
4. Is ingesting frankincense essential oil supplements daily safe, as measured by laboratory tests and adverse events?

Researchers will compare two types of frankincense essential oil supplements. One type contains frankincense essential oil and boswellic acid as its active ingredients. The other type contains only frankincense essential oil as its active ingredient.

Participants will:

* Be assigned one of the two types of frankincense essential oil supplement
* Take two capsules of their assigned supplement every day for about 30 days
* Attend two study visits in which they provide blood and urine samples, complete subjective health and quality of life assessments, and undergo anthropometric measurements
* Complete weekly subjective health assessments from home

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Frankincense essential oil + boswellic acid supplement

This supplement contains frankincense essential oil and boswellic acid as its active ingredients.

DIETARY_SUPPLEMENT

Frankincense essential oil supplement

This supplement contains frankincense essential oil as its active ingredient.

Sponsors & Collaborators

  • dōTERRA International

    lead INDUSTRY

Principal Investigators

  • Nicole Stevens, PhD · doTERRA International

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2024-08-12
Completion
2024-08-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488417 on ClinicalTrials.gov